Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
2.235
-0.245 (-9.88%)
At close: Apr 3, 2025, 4:00 PM
2.292
+0.057 (2.53%)
Pre-market: Apr 4, 2025, 4:05 AM EDT

Company Description

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.

The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics.

Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.

It has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities.

The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation
Absci logo
Country United States
Founded 2011
IPO Date Jul 22, 2021
Industry Biotechnology
Sector Healthcare
Employees 157
CEO Sean McClain

Contact Details

Address:
18105 SE Mill Plain Boulevard
Vancouver, Washington 98683
United States
Phone 360 949 1041
Website absci.com

Stock Details

Ticker Symbol ABSI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001672688
CUSIP Number 00091E109
ISIN Number US00091E1091
Employer ID 85-3383487
SIC Code 8731

Key Executives

Name Position
Sean McClain Founder, Chief Executive Officer, President and Director
Dr. Zachariah Jonasson Ph.D. Chief Business Officer and Chief Financial Officer
Dr. Andreas Busch Ph.D. Chief Innovation Officer and Member of Scientific Advisory Board
Todd Bedrick CPA Senior Vice President and Chief Accounting Officer
Alexander Khan CPA Vice President of Finance and Head of Investor Relations
Shelby Walker J.D. Chief Legal Officer
Karin Wierinck Chief People Officer
Melissa Patterson Ph.D. Chief of Staff
Wen Sha Chief of Staff
Dr. Christine Lemke D.V.M., M.B.A., Ph.D. Senior Vice President of Portfolio and Growth Strategy

Latest SEC Filings

Date Type Title
Apr 1, 2025 S-3 Registration statement under Securities Act of 1933
Mar 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 19, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Jan 15, 2025 8-K Current Report
Jan 10, 2025 SCHEDULE 13G Filing
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals